Alzheimer's Drugs Global Market Report 2025

Description

Alzheimer's drugs are medications designed to assist in the management of symptoms related to memory loss, cognitive issues, and daily functioning challenges associated with Alzheimer's disease-a progressive brain disorder characterized by a gradual decline in memory, reasoning, and learning abilities.

The primary drugs used for Alzheimer's treatment include donepezil, rivastigmine, galantamine, and memantine. Donepezil belongs to the class of drugs known as cholinesterase inhibitors. These medications are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They find application in treating different stages of Alzheimer's disease, ranging from the early to moderate stages to the moderate to severe stages.

The Alzheimer's drugs market research report is one of a series of new reports from The Business Research Company that provides Alzheimer's drugs market statistics, including Alzheimer's drugs industry global market size, regional shares, competitors with a Alzheimer's drugs market share, detailed Alzheimer's drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Alzheimer's drugs industry. This Alzheimer's drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alzheimer's drugs market size has grown strongly in recent years. It will grow from $9.33 billion in 2024 to $10.19 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to rise in Alzheimer's disease cases, investments in research and development, improved understanding of disease mechanisms, global health initiatives, public awareness and education.

The alzheimer's drugs market size is expected to see strong growth in the next few years. It will grow to $14.47 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to precision medicine approaches, focus on disease modification, biomarker identification and validation, patient-centric drug development, focus on non-pharmacological interventions. Major trends in the forecast period include diverse therapeutic approaches, digital health solutions, regenerative medicine, advancements in diagnostic technologies, artificial intelligence (AI) in drug discovery, partnerships and collaborations.

The increasing prevalence of Alzheimer's disease is anticipated to drive the growth of the Alzheimer's drugs market in the coming years. Alzheimer's disease is a progressive neurological condition that leads to brain shrinkage and cell death over time. Medications for Alzheimer's are designed to address memory loss, cognitive impairments, and challenges in daily living. These drugs can improve the quality of life and help individuals maintain their independence. For example, in May 2024, a report from the Alzheimer's Association, a US-based nonprofit focused on Alzheimer's care, support, and research, indicated that the number of Americans aged 65 and older diagnosed with Alzheimer's dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024.

The rising healthcare funding is projected to drive the growth of the Alzheimer's drugs market in the coming years. Increased funding in healthcare facilitates extensive research and development, supports clinical trials, enables advanced diagnostic technologies, and provides access to specialized healthcare services. It also implements awareness programs and develops necessary infrastructure. Furthermore, this funding plays a crucial role in enhancing patient access to medications and addressing the challenges related to Alzheimer's disease, fostering innovation in both drug development and patient care. For instance, in May 2023, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023.

Key players in the Alzheimer's drugs market are focusing on developing innovative treatments, such as amyloid plaque-targeting therapy, to enhance treatment options and improve patient outcomes. This therapy specifically targets the reduction or prevention of amyloid-beta plaque accumulation in the brain, which is associated with Alzheimer's disease. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval from the Food and Drug Administration (FDA) for Kisunla (donanemab-azbt). Kisunla is notable as the first and only amyloid plaque-targeting therapy designed for early symptomatic Alzheimer's disease. It functions by assisting the body in removing excess amyloid plaques from the brain, which are linked to cognitive decline in Alzheimer's patients. Kisunla is administered via intravenous infusion every four weeks, with an initial dosing regimen of 700 mg for the first three doses, followed by 1400 mg thereafter. It is specifically indicated for adults experiencing mild cognitive impairment (MCI) and mild dementia stages of Alzheimer's disease, contingent upon confirmed amyloid pathology.

Major companies operating in the alzheimer's drugs market are developing new combination therapies to sustain their position in the market. Combination therapies refer to the simultaneous use of two or more therapeutic agents or treatment modalities to address a medical condition. For instance, in April 2022, NovaMedica LLC, a Russia-based pharmaceutical company launched an innovative Alzheimer's disease therapy named MYOREOL. The drug, developed and registered by NovaMedica, is a combination of donepezil and memantine molecules, marking the first of its kind in Russia, the EAEU, and Europe. MYOREOL aims to enhance treatment retention and effectiveness in patients with moderate and severe dementia associated with Alzheimer's disease.

In March 2022, AbbVie, a US-based publicly traded biopharmaceutical company, acquired Syndesi Therapeutics for an undisclosed amount. This acquisition grants AbbVie access to Syndesi's portfolio of new modulators of the synaptic vesicle protein 2A (SV2A), including its lead compound SDI-118, and will aid in the expansion of AbbVie's neuroscience product line. Syndesis Therapeutics is a Belgium-based company that treats Alzheimer's disease and other disorders with cognitive impairment.

Major companies operating in the alzheimer's drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

North America was the largest region in the Alzheimer's drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer's drugs market during the forecast period. The regions covered in the alzheimer's drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the alzheimer's drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Alzheimer's drugs market consists of sales of cholinesterase inhibitors such as aricept, exelon, and razadyne. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alzheimer's Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alzheimer's drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alzheimer's drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alzheimer's drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drugs: Donepezil; Rivastigmine; Galantamine; Memantine
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) By Application: Early To Moderate Stages; Moderate To Severe Stages
Subsegments:
1) By Donepezil: Oral Tablets; Oral Solution
2) By Rivastigmine: Oral Capsules; Oral Solution; Transdermal Patches
3) By Galantamine: Oral Tablets; Oral Solution; Extended-Release Capsules
4) By Memantine: Oral Tablets; Oral Solution; Extended-Release Capsules
Companies Mentioned: AbbVie Inc.; Daiichi Sankyo Company Limited; F Hoffmann-La Roche AG; Merck & Co Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23135

1. Executive Summary

2. Alzheimer's Drugs Market Characteristics

3. Alzheimer's Drugs Market Trends And Strategies

4. Alzheimer's Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Alzheimer's Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Alzheimer's Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Alzheimer's Drugs Market Growth Rate Analysis
5.4. Global Alzheimer's Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Alzheimer's Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Alzheimer's Drugs Total Addressable Market (TAM)

6. Alzheimer's Drugs Market Segmentation

6.1. Global Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Donepezil
Rivastigmine
Galantamine
Memantine
6.2. Global Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.3. Global Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early To Moderate Stages
Moderate To Severe Stages
6.4. Global Alzheimer's Drugs Market, Sub-Segmentation Of Donepezil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablets
Oral Solution
6.5. Global Alzheimer's Drugs Market, Sub-Segmentation Of Rivastigmine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Capsules
Oral Solution
Transdermal Patches
6.6. Global Alzheimer's Drugs Market, Sub-Segmentation Of Galantamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablets
Oral Solution
Extended-Release Capsules
6.7. Global Alzheimer's Drugs Market, Sub-Segmentation Of Memantine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablets
Oral Solution
Extended-Release Capsules

7. Alzheimer's Drugs Market Regional And Country Analysis

7.1. Global Alzheimer's Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Alzheimer's Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Alzheimer's Drugs Market

8.1. Asia-Pacific Alzheimer's Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Alzheimer's Drugs Market

9.1. China Alzheimer's Drugs Market Overview
9.2. China Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Alzheimer's Drugs Market

10.1. India Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Alzheimer's Drugs Market

11.1. Japan Alzheimer's Drugs Market Overview
11.2. Japan Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Alzheimer's Drugs Market

12.1. Australia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Alzheimer's Drugs Market

13.1. Indonesia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Alzheimer's Drugs Market

14.1. South Korea Alzheimer's Drugs Market Overview
14.2. South Korea Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Alzheimer's Drugs Market

15.1. Western Europe Alzheimer's Drugs Market Overview
15.2. Western Europe Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Alzheimer's Drugs Market

16.1. UK Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Alzheimer's Drugs Market

17.1. Germany Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Alzheimer's Drugs Market

18.1. France Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Alzheimer's Drugs Market

19.1. Italy Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Alzheimer's Drugs Market

20.1. Spain Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Alzheimer's Drugs Market

21.1. Eastern Europe Alzheimer's Drugs Market Overview
21.2. Eastern Europe Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Alzheimer's Drugs Market

22.1. Russia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Alzheimer's Drugs Market

23.1. North America Alzheimer's Drugs Market Overview
23.2. North America Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Alzheimer's Drugs Market

24.1. USA Alzheimer's Drugs Market Overview
24.2. USA Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Alzheimer's Drugs Market

25.1. Canada Alzheimer's Drugs Market Overview
25.2. Canada Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Alzheimer's Drugs Market

26.1. South America Alzheimer's Drugs Market Overview
26.2. South America Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Alzheimer's Drugs Market

27.1. Brazil Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Alzheimer's Drugs Market

28.1. Middle East Alzheimer's Drugs Market Overview
28.2. Middle East Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Alzheimer's Drugs Market

29.1. Africa Alzheimer's Drugs Market Overview
29.2. Africa Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Alzheimer's Drugs Market Competitive Landscape And Company Profiles

30.1. Alzheimer's Drugs Market Competitive Landscape
30.2. Alzheimer's Drugs Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Alzheimer's Drugs Market Other Major And Innovative Companies

31.1. Biogen Inc.
31.2. AstraZeneca PLC
31.3. Eisai Co Ltd.
31.4. Eli Lilly and Company
31.5. H Lundbeck A/S
31.6. Pfizer Inc.
31.7. Allergan PLC.
31.8. Johnson & Johnson
31.9. Lupin Pharmaceuticals Inc.
31.10. Actiza Pharmaceutical Private Limited
31.11. Neurotrope Inc.
31.12. AC Immune SA
31.13. Adamas Pharmaceuticals Inc
31.14. Alzheon Inc.
31.15. Anavex Life Sciences Corp

32. Global Alzheimer's Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Alzheimer's Drugs Market

34. Recent Developments In The Alzheimer's Drugs Market

35. Alzheimer's Drugs Market High Potential Countries, Segments and Strategies

35.1 Alzheimer's Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Alzheimer's Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Alzheimer's Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer